Abstract. The Dual Chamber and VVI Implantable Defibrillator (DAVID) trial randomized 506 patients and tested the hypothesis that the dual-chamber pacing mode would produce improved hemodynamics and would in turn reduce congestive heart failure, heart failure hospitalizations, heart failure deaths, atrial fibrillation, strokes, ventricular arrhythmias, and total mortality compared to backup ventricular pacing in patients indicated for implantable defibrillator therapy. Patients had either primary prevention indications (47%) or secondary prevention indications (53%) for implantable defibrillator therapy but had no indications for bradycardia pacemaker support. All the patients had moderate to severe left ventricular dysfunction with a left ventricular ejection fraction of 40% or less (mean = 27%) and were consistently treated with angiotensin converting enzyme inhibitors or angiotensin II receptor blockers (86%) and beta adrenergic blocking agents (85%). The primary combined endpoint of hospitalization for congestive heart failure or death was paradoxically increased and statistically significant ( p= 0.03) at one year in the patients paced in the dual chamber mode (22.6%) compared to patients randomized to ventricular backup pacing (13.3%). Both heart failure hospitalization and mortality contributed outcome.
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Another perspective would consider this a randomized controlled study of presence or absence of pacemaker therapy in patients with left ventricular dysfunction and indications for implantable defibrillator therapy. Ventricular backup pacing produced less than 3% ventricular and no atrial pacing, while dual chamber pacing produced approximately 60% atrial and ventricular paced heart beats. The poor outcome in the dual chamber paced group correlated with the percentage of right ventricular pacing and suggests that right ventricular pacing caused ventricular dyssynchrony. The poor outcome associated with right ventricular pacing compared to intrinsic activation in the control group of the DAVID trial is reminiscent of the poor outcome associated with prolonged intraventricular conduction activation in the control groups compared to biventricular pacing in the intervention groups of the cardiac resynchronization trials.
The direct conclusion from these results are that patients with indications for implantable defibrillators and no indication for pacing should not be paced in the dual chamber pacing mode. It is not appropriate to conclude that only single chamber implantable defibrillators should be implanted. There are other potential advantages to having an implanted atrial lead including improved secondary outcomes. However the DAVID trial results suggest that the dual chamber paced mode was not associated with improved quality of life or decreased frequency of hospitalization, inappropriate shocks from the defibrillator or atrial fibrillation.
The more important question is what is the optimal pacing mode in these patients? The AAIR mode is under investigation in the DAVID II study in an attempt to identify a pacing mode that preserves atrio-ventricular synchrony, normal atrio-ventricular timing, prevents bradycardia and also prevents right ventricular stimulation.
Caution should be taken to not directly apply these results to patients with either an indication for pacemaker therapy or to patients with an indication for cardiac resynchronization therapy since patients from neither population were included. However, considering the large magnitude of the deleterious effects associated with dual chamber pacing in the DAVID trial future studies should explore the possibility that left ventricular stimulation may be the only pacing mode capable of preventing bradycardia without increasing death and congestive heart failure.
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The Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial:
A Randomized Trial
The implantable cardioverter defibrillator (ICD) improves survival for many patients with either the history of or significant risk for life-threatening ventricular arrhythmias [1] . However the randomized clinical trials designed to test the efficacy of ICD therapy were almost exclusively conducted before dual chamber pacing was integrated into the devices. Because few of these patients had indications for bradycardia pacing, virtually all of the patients had their devices programmed to backup ventricular (VVI at a slow rate) pacing. Consequently the impact of atrial or atrial-ventricular pacing had not been established in this patient population.
Before the Dual Chamber and VVI Implantable Defibrillator (DAVID) trial it was recognized that ventricular stimulation with pacemakers could adversely affect ventricular contraction, but the frequency and magnitude adverse effects had not been quantified. However, pacemakers often are implanted in patients with modest degrees of sinus node dysfunction and first degree AV block when negative chronotropic and dromotropic medications are prescribed for coronary artery disease, hypertension, left ventricular dysfunction or atrial and ventricular tachyarrhythmias. The DAVID trial tested the hypothesis that dual-chamber pacing would permit optimal drug therapy and improve hemodynamics and would in turn reduce CHF, heart failure hospitalizations, heart failure deaths, atrial fibrillation, strokes, ventricular arrhythmias, and total mortality compared to backup ventricular pacing (VVI) in ICD patients [2] . The investigators thought that the advantages of avoiding bradycardia during aggressive pharmacologic treatment of an ICD population with significant left ventricular dysfunction and no overt indications for pacemaker therapy would outweigh the potential disadvantages associated with right ventricular stimulation. The results of the trial proved the hypothesis incorrect.
Methods
Technically, the DAVID Trial was a multicenter, randomized, single-blinded, parallel study of patients with ICDs, comparing VVI and DDDR paced modes [3] . The DAVID trial was multicenter, randomized, parallel, controlled evaluation of pacemaker therapy in patients with left ventricular dysfunction and indications for ICD therapy. Enrollment began in October 2000 and concluded at the recommendation of the data safety monitoring board on September 30, 2002.
Participants and ICD implantation
All patients had a standard indication for ICD implantation, including a history of either spontaneous or inducible sustained ventricular tachyarrhythmias but without an indication for antibradycardia pacing. Transvenous dual-chamber pacemaker ICDs (Photon, Photon Micro, or Photon Atlas, St Jude Medical Inc, Sylmar, Calif) were implanted with a minimal defibrillation safety margin of 10 J. A high risk population of ICD patients was included by requiring every patient to have an LVEF of ≤40%.
Randomization
After ICD implantation, patients were randomly assigned to the VVI mode with a lower rate of 40/min (VVI-40) or to the DDDR mode with a lower rate of 70/min (DDDR-70). Only the DDDR-70 group had activation of supraventricular tachycardia detection enhancements. This single-blind randomization (the patient was blinded to pacing mode) was stratified by site, history of CHF, and history of atrial fibrillation.
Programming
The prescribed programmed parameters are described in Table 1 . The investigators had freedom to program all other parameters as clinically indicated.
Heart failure drug therapy
Pharmacologic therapy for left ventricular dysfunction and heart failure consisted of digoxin, diuretics, ACE inhibitors, and β-blockers in the doses described in Table 2 .
Objectives and outcome measures
The combined primary end point was freedom from death or hospitalization for heart failure.
Statistical methods
The DAVID Trial used a 2-sided α = .05 level test of the null hypothesis with monitoring for early rejection of the null hypothesis. The null hypothesis was that the time to death or hospitalization for treatment of heart failure would be similar in both treatment groups. Comparison was based on intentionto-treat. The log-rank statistic was the test statistic. The anticipated sample size was 800 subjects.
Results

Baseline characteristics
A total of 506 patients were enrolled and randomized in the trial. The baseline characteristics of the randomized patients are similar to ICD recipients in previous trials. The mean LVEF was 27% (patients with LVEF of >40% were excluded). Nearly one half of the patients were NYHA functional class I, 39% were NYHA class II, and only approximately 12% were functional class III-IV. The mean intrinsic QRS duration was 120 ms and 30.8% of patients had a QRS duration of at least 130 ms. Right and left bundle-branch pattern was present in 11.0% and 16.5% respectively. The baseline characteristics were well balanced in the 2 randomized groups.
Pharmacologic therapy for left ventricular dysfunction was balanced between groups at initial hospital discharge after randomization and throughout the study [2] . Eighty-five per cent of both randomized groups received beta adrenergic blockade.
Follow-up data
Median follow-up was 8.4 months (range, 0-23.6 months). The cumulative percentage of ventricular stimulation over time is displayed in Table 3 .
